Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909163 | 0.89 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10TP53 | |
| SCHEMBL9907552 | 0.88 | GAA (0.54) | ALDH1A1KDM4EHPGDHSD17B10TP53 | |
| SCHEMBL9105440 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDHSD17B10TP53 | |
| SCHEMBL9909278 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10TP53 | |
| SCHEMBL13537289 | 0.80 | NPC1 (0.49) | ALDH1A1KDM4EHPGDHSD17B10NPC1 | |
| SCHEMBL6883943 | 0.79 | NPC1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL227343 | 0.78 | RAB9A (0.50) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL31428597 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10TP53 | |
| SCHEMBL13209990 | 0.78 | KDM4E (0.41) | ALDH1A1KDM4EHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL16621161 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | ALDH1A1 1799/4885KDM4E 1474/4885HPGD 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.